| Biologic therapy for psoriasis: an update on the tumor necrosis factor inhibitors infliximab, etanercept, and adalimumab, and the T-Cell-targeted therapies ... from: Journal of Drugs in Dermatology | Digitalby Jeffrey M. Weinberg (Author), Clement J. Bottino (Author), James Lindholm (Author), Robin Buchholz (Author)
| List Price: | $5.95 | | | Available: | Available for download now |
| | Binding: | Digital | | Publisher: | Thomson Gale | | Page Count: | 26 Pages | | Publication Date: | September 01, 2005 | | Sales Rank: | 6,202,193th |
|
EDITORIAL REVIEWS |
Product Description
This digital document is an article from Journal of Drugs in Dermatology, published by Thomson Gale on September 1, 2005. The length of the article is 7602 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.Citation DetailsTitle: Biologic therapy for psoriasis: an update on the tumor necrosis factor inhibitors infliximab, etanercept, and adalimumab, and the T-Cell-targeted therapies efalizumab and alefacept.Author: Jeffrey M. WeinbergPublication: Journal of Drugs in Dermatology (Magazine/Journal)Date: September 1, 2005Publisher: Thomson GaleVolume: 4 Issue: 5 Page: 544(12)Distributed by Thomson Gale |
|
